Lotus Eye Hospital & Institute Ltd

NSE: LOTUSEYE BSE: 532998Healthcare

Incorporated in 1990, Lotus Eye Hospital and Institute Ltd provides ophthalmology and other related services.[1]

₹105

52W: ₹67.7 — ₹148

PE 337 · Book ₹29.2 · +260% vs book

Market Cap₹219 Cr

Stock P/E337Price to Earnings

ROCE2.99%Return on Capital

ROE1.22%Return on Equity

Div. Yield0%Face Value ₹10

Strengths

−Stock is trading at 3.56 times its book value
−Though the company is reporting repeated profits, it is not paying out dividend
−Promoter holding has decreased over last quarter: -0.53%
−The company has delivered a poor sales growth of 4.09% over past five years.
−Company has a low return on equity of 4.43% over last 3 years.
−Promoters have pledged 87.2% of their holding.
−Earnings include an other income of Rs.1.22 Cr.

Promoters40.14%

FIIs0%

DIIs0.02%

Public59.85%

Category	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Promoters	40.24%	40.03%▼0.2	40.14%▲0.1	40.22%▲0.1	40.39%▲0.2	40.63%▲0.2	40.66%▲0.0	40.14%▼0.5
FIIs	0%	0%	0%	0%	0.01%▲0.0	0%▼0.0	0.01%▲0.0	0%▼0.0
DIIs	0%	0%	0.04%▲0.0	0.04%	0.02%▼0.0	0.02%	0.02%	0.02%
Public	59.76%	59.97%▲0.2	59.82%▼0.1	59.73%▼0.1	59.57%▼0.2	59.33%▼0.2	59.31%▼0.0	59.85%▲0.5

Metric	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	12.73	12.03	10.88	12.89	12.91	12.25	11.51	13.52	13.04	13.55
Expenses	10.92	10.45	10.12	11.23	11.76	11.46	11.68	12.04	12.27	12.89
Operating Profit	1.81	1.58	0.76	1.66	1.15	0.79	-0.17	1.48	0.77	0.66
OPM %	14.22%	13.13%	6.99%	12.88%	8.91%	6.45%	-1.48%	10.95%	5.9%	4.87%
Net Profit	0.85	0.66	0.02	0.62	0.1	-0.24	0.25	0.54	0.12	-0.26
EPS ₹	0.41	0.32	0.01	0.3	0.05	-0.12	0.12	0.26	0.06	-0.13

Revenue Trend

TTM revenue at ₹51.62Cr, up 4.2% YoY. OPM at 5.31%.

Debt Position

Borrowings at ₹4.8Cr. Debt-to-equity ratio: 0.12x. Healthy balance sheet.

Capex Cycle

CWIP at ₹0.06Cr (0% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 0.02% (+0.02pp change). FIIs: 0% (+0.00pp change). Promoters hold 40.14%.

Margin & Efficiency

ROCE improving from 0.27% (Mar 2014) to 2.99% (Mar 2025). Working capital days: 0.

Valuation

PE 337x with 2.99% ROCE. Price is 260% above book value of ₹29.2. Dividend yield: 0%.